To Be Discontinued Injection Hematology
Plerixafor Injection · 182 days since initial FDA posting
Brand: PLERIXAFOR
FDA lists Plerixafor Injection as To Be Discontinued (Fresenius Kabi USA, LLC).
No availability text on this FDA row.
Plerixafor Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Plerixafor Injection
- Manufacturer
- Fresenius Kabi USA, LLC
- Dosage Form
- Injection
- Presentation
- Plerixafor, Injection, 24 mg per 1.2 mL (20 mg per mL) (NDC 65219-284-12)
- Package NDC
- 65219-284-12
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Mar 13, 2026
- Last Updated
- Mar 13, 2026
- Therapeutic Category
- Hematology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
A business decision was made to discontinue manufacture of the drug.
FDA reason on file: A business decision was made to discontinue manufacture of the drug. General shortage guidance lives on the tracker hub.